Estrogen regulates histone deacetylases to prevent cardiac hypertrophy

Molecular Biology of the Cell

Volumn 24, Issue 24, 2013, Pages 3805-3818

  Pedrama, Ali ^a   Razandi, Mahnaz ^b   Narayanan, Ramesh ^c   Dalton, James T ^c   McKinsey, Timothy A ^d   Levin, Ellis R ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^c GTx Inc   (United States)

^d UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; ESTRADIOL; ESTROGEN RECEPTOR BETA; HISTONE DEACETYLASE; MESSENGER RNA; BETA-LGND2; ESTROGEN; GATA4 PROTEIN, HUMAN; HDAC2 PROTEIN, HUMAN; HDAC4 PROTEIN, HUMAN; HDAC5 PROTEIN, HUMAN; HISTONE DEACETYLASE 2; ISOQUINOLINE DERIVATIVE; PROTEIN KINASE C DELTA; REPRESSOR PROTEIN; TRANSCRIPTION FACTOR GATA 4;

AGONIST; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DISEASE COURSE; ENZYME PHOSPHORYLATION; FEMALE; GENE EXPRESSION; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; RAT; SIGNAL TRANSDUCTION; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; C57BL MOUSE; CARDIOMEGALY; CELL CULTURE; DRUG EFFECTS; GENETICS; HEART; PHOSPHORYLATION; PHYSIOLOGY; TRANSCRIPTION INITIATION;

ANGIOTENSIN II; ANIMALS; CARDIOMEGALY; CELLS, CULTURED; ESTRADIOL; ESTROGEN RECEPTOR BETA; ESTROGENS; FEMALE; GATA4 TRANSCRIPTION FACTOR; HEART; HISTONE DEACETYLASE 2; HISTONE DEACETYLASES; ISOQUINOLINES; MICE; MICE, INBRED C57BL; MYOCYTES, CARDIAC; PHOSPHORYLATION; PROTEIN KINASE C-DELTA; RATS; REPRESSOR PROTEINS; RNA, MESSENGER; TRANSCRIPTIONAL ACTIVATION;

EID: 84890487889     PISSN: 10591524     EISSN: 19394586     Source Type: Journal    
DOI: 10.1091/mbc.E13-08-0444     Document Type: Article

References (61)

1. Agabiti-Rosei E, Muiesan ML (2002). Left ventricular hypertrophy and heart failure in women. J Hypertens 20, S34-S38.
2. Akazawa H, Komuro I (2003). Roles of cardiac transcription factors in cardiac hypertrophy. Circ Res 92, 1079-1088.
3. Antos CL, McKinsey TA, Dreitz M, Hollingsworth LM, Zhang CL, Schreiber K, Rindt H, Gorczynski RL, Olson EN (2003). Dose-dependent blockade to cardiomyocyte hypertrophy by histone ase inhibitors. J Biol Chem 278, 28930-28937.
4. Antos CL, McKinsey TA, Frey N, Kutsdchke W, McAnally J, Shelton JM, Richardson JA, Hill JA, Olson EN (2002). Activated glycogen synthase-3β suppresses cardiac hypertrophy in vivo. Proc Natl Acad Sci USA 99, 907-912.
5. Babiker FA, Lips D, Meyer R, Delvaux E, Zandberg P, Janssen B, van Eys G, Grohe C, Doevendans PA (2006). Estrogen receptor β protects the murine heart against left ventricular hypertrophy. Arterioscler Thromb Vasc Biol 26, 1524-1530.
6. Backs J, Olson EN (2006). Control of cardiac growth by histone acetylation/deacetylation. Circ Res 98, 15-24.
7. Backs J, Song K, Bezprpzvannaya S, Chang S, Olson EN (2006). CAM kinase II selectively signals to histone deacetylase 4 during cardiomyocyte hypertrophy. J Clin Invest 116, 1853-1864.
8. Berridge MJ (2006). Remodeling Ca2+ signaling systems and cardiac hypertrophy. Biochem Soc Trans 34, 228-231.
9. Bisping E, Ikeda S, Sedej M, Wakula P, McMullen JR, Tarnavski O, Sedej S, Izumo S, Pu WT, Pieske B (2012). Transcription factor GATA4 is activated but not required for insulin-like growth factor 1 (IGF1)-induced cardiac hypertrophy. J Biol Chem 287, 9827-9834.
10. Chang S, McKinsey TA, Zhang CL, Richardson JA, Hill JA, Olson EN (2004). Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development. Mol Cell Biol 24, 8467-8476.
11. Cruciat C-M, Dolde C, de Groot REA, Ohkawara B, Reinhard C, Korswagen HC, Niehrs C (2013). RNA helicase DDX3 is a regulatory subunit of casein kinase 1 in Wnt-b-catenin signaling. Science 339, 1436-1441.
12. Dent MR, Tappia PS, Dhalla NS (2010). Gender differences in cardiac dysfunction and remodeling due to volume overload. J Card Fail 16, 439-449.
13. Dunn FG, Pfeffer MA (1999). Left ventricular hypertrophy in hypertension. N Engl J Med 340, 1279-1280.
14. Eom GH et al. (2011). Casein kinase-2α1 induces hypertrophic response by phosphorylation of histone deacetylase 2 S394 and its activation in the heart. Circulation 123, 2392-2403.
15. Favre J, Gao J, Henry JP, Remy-Jouet I, Fourquaux I, Billon-Gales A, Thulliez C, Arnal JF, Lenfant F, Richard V (2010). Endothelial estrogen receptor alpha plays an essential role in the coronary and myocardial protective effects of estradiol in ischemia/reperfusion. Arterioscler Thromb Vasc Biol 12, 2562-2567.
16. Fischle W, Dequiedt F, Hendzel MJ, Guenther MG, Lazar MA, Voelter W, Verdin E (2002). Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. Mol Cell 9, 45-57.
17. Fliegner D et al. (2010). Female sex and estrogen receptor-beta attenuate cardiac remodeling and apoptosis in pressure overload. Am J Physiol Regul Integr Comp Physiol 298, R1597-R1606.
18. Gardner JD, Murray DB, Voloshenyuk TG, Brower GL, Bradley JM, Janicki JS (2010). Estrogen attenuates chronic volume overload induced structural and functional remodeling in male rat hearts. Am J Physiol Heart Circ Physiol 298, H497-H504.
19. Haberland M, Montgomery RL, Olson EN (2009). The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet 10, 32-42.
20. Harrison BC, Roberts CR, Hood DB, Sweeney M, Gould JM, Bush EW, McKinsey TA (2004). The CRM1 nuclear export receptor controls pathological cardiac gene expression. Mol Cell Biol 24, 10636-10649.
21. Heineke J, Molkentin JD (2006). Regulation of cardiac hypertrophy by intracellular signaling pathways. Nat Rev Mol Cell Biol 7, 589-600.
22. Jazbutyte V et al. (2007). Ligand-dependent activation of ERbeta lowers blood pressure and attenuates cardiac hypertrophy in ovariectomized SHR. Cardiovasc Res 77, 774-781.
23. Joiner MA et al. (2012). CaMKII determines mitochondrial stress responses in heart. Nature 491, 269-273.
24. Kee HJ et al. (2006). Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding. Circulation 113, 51-59.
25. Kong Y, Tannous P, Lu G, Berenji K, Rothermel BA, Olson EN, Hill JA (2006). Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy. Circulation 113, 2579-2588.
26. Kramerov AA, Golub AG, Bdzhola VG, Yarmoluk SM, Ahmed K, Bretner M, Ljubimov AV (2011). Treatment of cultured human astrocytes and vascular endothelial cells with protein kinase CK2 inhibitors induces early changes in cell shape and cytoskeleton. Mol Cell Biochem 349, 125-137.
27. Kumar P, Wu Q, Chambliss KL, Yuhanna IS, Mumby SM, Mineo C, Tall GG, Shaul PW (2007). Direct interactions with Gαi and Gβγ mediate nongenomic signaling by estrogen receptor β. Mol Endocrinol 21, 1370-1380.
28. Light KC, Hinderliter AL, West SG, Grewen KM, Steege JF, Sherwood A, Girdler SS (2001). Hormone replacement improves hemodynamic profile and left ventricular geometry in hypertensive and normotensive postmenopausal women. J Hypertens 19, 269-278.
29. Lim WK, Wren B, Jepson N, Roy S, Caplan G (1999). Effect of hormone replacement therapy on left ventricular hypertrophy. Am J Cardiol 83, 1132-1134.
30. Livak KJ, Schmittgen TD (2001). Analysis of relative gene expression data using real-time, quantitative PCR and the 2 ⊗⊗XT method. Methods 25, 402-408.
31. Lompre AM, Schwartz K, d'Albis A, Lacombe G, Thiem NV, Swynghedauw B (1979). Myosin isozymes redistribution in chronic heart overloading. Nature 282, 105-107.
32. McKinsey TA (2011). Isoform-selective HDAC inhibitors: closing in on translational medicine for the heart. J Mol Cell Cardiol 51, 491-496.
33. McKinsey TA, Olson EN (2005). Toward transcriptional therapies for the failing heart: chemical screens to modulate genes. J Clin Invest 115, 538-546.
34. Miya Y, Sumino H, Ichikawa S, Nakamura T, Kanda T, Kumakura H, Takayama Y, Mizunuma H, Sakamaki T, Kurabayashi M (2002). Effects of hormone replacement therapy on left ventricular hypertrophy and growth-promoting factors in hypertensive postmenopausal women. Hypertens Res 25, 153-159.
35. Morisco C, Seta K, Hardt SE, Lee Y, Vatner SF, Sadoshima J (2001). Glycogen synthase kinase 3β regulates GATA4 in cardiac myocytes. J Biol Chem 276, 28586-28597.
36. Pedram A, Razandi R, Aitkenhead M, Levin ER (2005). Estrogen inhibits cardiomyocyte hypertrophy in-vitro: antagonism of calcineurin-related hypertrophy through induction of MCIP1. J Biol Chem 280, 26339-26348.
37. Pedram A, Razandi M, Deschenes R, Levin ER (2012). DHHC 7 and 21 are palmitoylacyltranferases for sex steroid receptors. Mol Biol Cell 23, 188-199.
38. Pedram A, Razandi M, Kim JK, O'Mahony F, Lee E, Luderer U, Levin ER (2009). Developmental phenotype of a membrane only estrogen receptor α (MOER) mouse. J Biol Chem 284, 3488-3495.
39. Pedram A, Razandi M, Korach KS, Narayanan R, Dalton JT, Levin ER (2013). ERβ selective agonist inhibits angiotensin-induced cardiovascular pathology in female mice. Endocrinology 154, 4352-4364.
40. Pedram A, Razandi M, Lubahn D, Liu J, Vannan M, Levin ER (2008). Estrogen inhibits cardiac hypertrophy: role of estrogen receptor beta to inhibit calcineurin. Endocrinology 149, 3361-3369.
41. Pedram A, Razandi M, O'Mahony F, Lubahn D, Levin ER (2010). Estrogen receptor beta prevents cardiac fibrosis. Mol Endocrinol 24, 2152-2165.
42. Pedram A, Razandi M, Wallace DC, Levin ER (2006). Functional estrogen receptors in the mitochondria of breast cancer cells. Mol Biol Cell 17, 2125-2137.
43. Razandi M, Pedram A, Jordan VC, Fuqua S, Levin ER (2013). Tamoxifen regulates cell fate through mitochondrial estrogen receptor beta in breast cancer. Oncogene 32, 3274-3285.
44. Rooij EV, Sutherland FJ, Thijssen VL, Crijns HJ, Dimaio MJ, Shelton J, De Windt LJ, Hill JA, Olson EN (2010). Myocyte enhancer factor 2 and class II histone deacetylases control a gender-specific pathway of cardioprotection mediated by the estrogen receptor. Circ Res 106, 155-165.
45. Skavdahl M, Steenbergen C, Clark J, Myers P, Demianenko T, Mao L, Rockman HA, Korach KS, Murphy E (2005). Estrogen receptor-β mediates male-female differences in the development of pressure overload hypertrophy. Am J Physiol Heart Circ Physiol 288, H469-H476.
46. Song K, Backs J, McAnally J, Qi X, Gerard RD, Richardson JA, Hill JA, Bassel-Duby R, Olson EN (2006). The transcriptional coactivator CAMTA2 stimulates cardiac growth by opposing class II histone deacetylases. Cell 125, 453-466.
47. Suganuma T, Mushegian A, Swanson SK, Abmayr SM, Florens L, Washburn MP, Workman JL (2010). The ATAC acetyltransferase complex coordinates MAP kinases to regulate JNK target genes. Cell 142, 726-736.
48. Trivedi CM et al. (2007). HDAC2 regulates the cardiac hypertrophic response by modulating GSK3β activity. Nat Med 13, 324-331.
49. van Eickels M, Grohe C, Cleutjens JP, Janssen BJ, Wellens HJ, Doevendans PA (2002). 17beta-Estradiol attenuates the development of pressure-overload hypertrophy. Circulation 104, 1419-1423.
50. Vega RB, Harrison BC, Meadows E, Roberts CR, Papst PJ, Olson EN, McKinsey TA (2004). Protein kinases C and D mediate agonist-dependent cardiac hypertrophy through nuclear export of histone deacetylase 5. Mol Cell Biol 24, 8374-8385.
51. Wagenaar LJ, Voors AA, Buikema H, van Gilst WH (2002). Angiotensin receptors in the cardiovascular system. Can J Cardiol 18, 1331-1339.
52. Wang F, Zhang Y, Jiang X, Zhang Y, Zhang L, Gong S, Liu C, Zhou L, Tao J (2011). Neuromedin U inhibits T-type Ca2+ channel currents and decreases membrane excitability in small dorsal root ganaglia neurons in mice. Cell Calcium 49, 12-22.
53. Wilkins BJ, De Windt LJ, Bueno OF, Braz JC, Glascock BJ, Kimball TF, Molkentin JD (2002). Targeted disruption of NFATc3, but not NFATc4, reveals an intrinsic defect in calcineurin-mediated cardiac hypertrophic growth. Mol Cell Biol 22, 7603-7613.
54. Xu X, Ha C-H, Wong C, Wang W, Hausser A, Pfizenmaier K, Olson EN, McKinsey TA, Jin Z-G (2007). Angiotensin II stimulates protein kinase D-dependent histone deacetylase 5 phosphorylation and nuclear export leading to vascular smooth muscle cell hypertrophy. Arterioscler Thromb Vasc Biol 27, 2355-2362.
55. Yang SH et al. (2004). Mitochondrial localization of estrogen receptor beta. Proc Natl Acad Sci USA 101, 4130-4135.
56. Yepuru M, Eswaraka J, Kearby JD, Barrett CM, Raghow S, Veverka KA, Miller DD, Dalton JT, Narayanan R (2010). Estrogen receptor beta selective ligands alleviate high-fat diet and ovariectomy-induced obesity in mice. J Biol Chem 285, 31292-31303.
57. Zhang CL, McKinsey TA, Chang S, Antos CL, Hill JA, Olson EN (2002). Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 110, 479-488.
58. Zhang L, Malik S, Pang J, Wang H, Park KM, Yule DI, Blaxell BC, Smrcka AV (2013). Phospholipase Cε hydrolyzes perinuclear phosphatidylinositol 4-phosphate to regulate cardiac hypertrophy. Cell 153, 216-227.
59. Zhao Y, Fang Q, Starub SG, Lindau M, Sharp GW (2010). Noradrenaline inhibits exocytosis via the G protein bg subunit and refilling of the readily releasable granule pool via the a(i1/2) subunit. J Physiol 288, 3485-3498.
60. Zhou P, He A, Pu WT (2012). Regulation of GATA4 transcriptional activity in cardiovascular development and disease. Curr Top Dev Biol 100, 143-169.
61. Zhu Y et al. (2002). Abnormal vascular function and hypertension in mice deficient in estrogen receptor beta. Science 295, 505-508.